Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling

Artificial intelligence, among other technological advances, is pushing innovation boundaries.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

More than 6000 rare diseases—those which affect fewer than one in 2000 people each—are acknowledged in the medical community, with 72% of them being genetic.

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Treatments for autoimmune diseases, multiple cancers, and skin blistering have been recommended for marketing approval.

While the boards of directors of both companies have approved the transaction, it is not expected to close until the second quarter of 2025, as Mayne Pharma’s shareholders must still vote in favor of the acquisition.